Quality control of [177Lu]Lu-PSMA preparations using HPLC: effect of sample composition and ligand on recovery

被引:1
作者
Aalbersberg, Else A. [1 ]
Cao, Tammie T. [1 ,3 ]
Geluk-Jonker, Martine M. [1 ,2 ]
Hendrikx, Jeroen J. M. A. [1 ,2 ]
机构
[1] Netherlands Canc Inst, Dept Nucl Med, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands
[2] Netherlands Canc Inst, Dept Pharm & Pharmacol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands
[3] OLVG Locatie West, Dept Pharmacol, Jan Tooropstr 164, NL-1061 AE Amsterdam, Netherlands
关键词
PSMA; Lu-177]Lu-PSMA-I&T; Lu-177]Lu-PSMA-617; HPLC; Column interaction; RADIOCHEMICAL PURITY; VALIDATION;
D O I
10.1186/s41181-022-00178-9
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background [Lu-177]Lu-PSMA is used for the treatment of metastatic castration-resistant prostate cancer. For in-house productions, quality control methods are essential for ensuring product quality, and thus patient safety. During HPLC method development for quality control of [Lu-177]Lu-PSMA-I&T, we noticed an unpredictable variability in peak area and height with replicate measurements. After a run, irremovable radioactivity was measured over the whole the length of the HPLC column, with slightly higher activity at the beginning and end of the column. The uniform distribution suggests that [Lu-177]Lu-PSMA-I&T interacts with the column. As a result of the interaction, incomplete and variable recovery of injected activity was observed leading to the variability in peak area and height. Therefore the aim of this study was to (1) investigate the effect of sample composition on the interaction of [Lu-177]Lu-PSMA-I&T to the HPLC column (measured as recovery, peak area, and peak height), and (2) to compare this with same concentrations of the well-known [Lu-177]Lu-PSMA-617. Results Sample composition significantly affects recovery of [Lu-177]Lu-PSMA-I&T, leading to a change in peak area and height. Recovery was 24% when diluted with 0.1 mM octreotide, 38% with water, and increased to 95% when diluted with 0.7 mM unlabeled PSMA-I&T. Peak area and height decreased to 26% and 17% when diluted in octreotide and to 41% and 29% when diluted in water, compared to a dilution in PSMA-I&T. Further experiments showed that recovery (and consequently peak area and peak height) reached a plateau of > 99% at concentrations of 0.27 mM and higher. [Lu-177]Lu-PSMA-617 also interacts with the HPLC column, leading to lower, but less variable, recovery (9%). The low recovery of [Lu-177]Lu-PSMA-617 could not be prevented with addition of unlabeled PSMA-617. Conclusion [Lu-177]Lu-PSMA-I&T can undergo an irreversible binding with an HPLC column resulting in a decreased recovery. The recovery is can be highly dependent on sample composition. The addition of a surplus of unlabeled PSMA-I&T leads to an accurate analysis of [Lu-177]Lu-PSMA-I&T.
引用
收藏
页数:10
相关论文
共 20 条
  • [1] Automated synthesis and quality control of [99mTc]Tc-PSMA for radioguided surgery (in a [68Ga]Ga-PSMA workflow)
    Aalbersberg, Else A.
    van Andel, Lotte
    Geluk-Jonker, Martine M.
    Beijnen, Jos H.
    Stokkel, Marcel P. M.
    Hendrikx, Jeroen J. M. A.
    [J]. EJNMMI RADIOPHARMACY AND CHEMISTRY, 2020, 5 (01)
  • [2] PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
    Afshar-Oromieh, A.
    Malcher, A.
    Eder, M.
    Eisenhut, M.
    Linhart, H. G.
    Hadaschik, B. A.
    Holland-Letz, T.
    Giesel, F. L.
    Kratochwil, C.
    Haufe, S.
    Haberkorn, U.
    Zechmann, C. M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (04) : 486 - 495
  • [3] Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden
    Aly, Markus
    Leval, Amy
    Schain, Frida
    Liwing, Johan
    Lawson, Joe
    Vago, Emese
    Nordstrom, Tobias
    Andersson, Therese M. -L.
    Sjoland, Erik
    Wang, Chen
    Eloranta, Sandra
    Akre, Olof
    [J]. SCANDINAVIAN JOURNAL OF UROLOGY, 2020, 54 (02) : 115 - 121
  • [4] [Anonymous], 2021, EUROPEAN PHARMACOPOE
  • [5] [Anonymous], 2017, The European Pharmacopoeia (Ph Eur)
  • [6] European Pharmacopoeia, 2018, GUID EL MON RAD PREP
  • [7] Standardization of the [68Ga]Ga-PSMA-11 Radiolabeling Protocol in an Automatic Synthesis Module: Assessments for PET Imaging of Prostate Cancer
    Fuscaldi, Leonardo L.
    Sobral, Danielle V.
    Durante, Ana Claudia R.
    Mendonca, Fernanda F.
    Miranda, Ana Claudia C.
    da Cunha, Marcelo L.
    Malavolta, Luciana
    Mejia, Jorge
    de Barboza, Marycel F.
    [J]. PHARMACEUTICALS, 2021, 14 (05)
  • [8] Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals
    Gillings, Nic
    Hjelstuen, Olaug
    Ballinger, Jim
    Behe, Martin
    Decristoforo, Clemens
    Elsinga, Philip
    Ferrari, Valentina
    Peitl, Petra Kolenc
    Koziorowski, Jacek
    Laverman, Peter
    Mindt, Thomas L.
    Neels, Oliver
    Ocak, Meltem
    Patt, Marianne
    Todde, Sergio
    [J]. EJNMMI RADIOPHARMACY AND CHEMISTRY, 2021, 6 (01)
  • [9] EANM guideline on the validation of analytical methods for radiopharmaceuticals
    Gillings, Nic
    Todde, Sergio
    Behe, Martin
    Decristoforo, Clemens
    Elsinga, Philip
    Ferrari, Valentina
    Hjelstuen, Olaug
    Peitl, Petra Kolenc
    Koziorowski, Jacek
    Laverman, Peter
    Mindt, Thomas L.
    Ocak, Meltem
    Patt, Marianne
    [J]. EJNMMI RADIOPHARMACY AND CHEMISTRY, 2020, 5 (01)
  • [10] Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
    Hooijman, Eline L.
    Chalashkan, Yozlem
    Ling, Sui Wai
    Kahyargil, Figen F.
    Segbers, Marcel
    Bruchertseifer, Frank
    Morgenstern, Alfred
    Seimbille, Yann
    Koolen, Stijn L. W.
    Brabander, Tessa
    de Blois, Erik
    [J]. PHARMACEUTICS, 2021, 13 (05)